title: Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma.
abstract: Targeting the hypoxia response pathway and angiogenesis are two promising therapeutic strategies for cancer treatment. Their use as single strategies has important limitations. Thus, development of combined regimens has become an important step toward improving therapeutic efficacy. Also, non-invasive monitoring of the response to targeted biological therapies, as well as determination of the optimal schedule for combination regimens has become an active field of research over the last five years, with relevance for both preclinical and clinical settings. Here, we used an optical imaging method to non-invasively monitor the functional changes in HIF activity in response to antiangiogenic treatment in a xenograft model of human ovarian carcinoma. A bioluminescent reporter construct containing nine copies of the hypoxia response element upstream of the luciferase gene (9xHRE-luciferase) was characterized in vitro in a panel of tumor cell lines and in vivo in a subcutaneous xenograft model of ovarian carcinoma by means of optical imaging. We showed that in OVCAR-3 subcutaneous xenografts, the most abrupt change in the HIF functional reporter occurs before the onset of massive tumor growth. However, this system failed to detect hypoxia induced upon antiangiogenic treatment due to the compensating effects of increased hypoxia and decreased tumor cell viability caused by imbalanced neovascularization vs. tumor expansion. Therefore, the readout based on HIF functional reporter could be conditioned by the dynamics of tumor growth and angiogenesis, which is highly variable depending on the tumor type, tumor model and stage of progression.
authors.affiliation: Departamento de Bioquímica, Instituto de Investigaciones Biomédicas (CSIC-UAM), 28029 Madrid, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Martinez-Poveda
authors.forename: V
authors.initials: V
authors.lastname: Gomez
authors.forename: M
authors.initials: M
authors.lastname: Alcaide-German
authors.forename: S
authors.initials: S
authors.lastname: Perruca
authors.forename: S
authors.initials: S
authors.lastname: Vazquez
authors.forename: L E
authors.initials: LE
authors.lastname: Alba
authors.forename: O
authors.initials: O
authors.lastname: Casanovas
authors.forename: M L
authors.initials: ML
authors.lastname: Garcia-Bermejo
authors.forename: L
authors.initials: L
authors.lastname: Peso
authors.forename: B
authors.initials: B
authors.lastname: Jimenez
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000068258:Bevacizumab; D015687:Cell Hypoxia / Q000502:physiology; D045744:Cell Line, Tumor; D005260:Female; D006367:HeLa Cells; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000032:analysis / Q000096:biosynthesis*; D021621:Imaging, Three-Dimensional / Q000379:methods; D008156:Luciferases / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D041622:Tomography, Optical / Q000379:methods*; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D051793:Hypoxia-Inducible Factor 1; D000068258:Bevacizumab; D008156:Luciferases